Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by Medical University of Vienna.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Markus Zeitlinger, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01414959
First received: August 10, 2011
Last updated: September 5, 2011
Last verified: September 2011
  Purpose

The investigators will measure the pharmacokinetics of doripenem in skeletal muscle, subcutaneous adipose tissue, bronchoalveolar lavage and plasma of intubated intensive care patients.


Condition
Pneumonia
Abdominal Infection
Urinary Tract Infection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Biospecimen Retention:   Samples Without DNA

plasma broncheoalvoeolar lavage microdialysates


Estimated Enrollment: 16
Study Start Date: August 2011
Estimated Study Completion Date: July 2013
Detailed Description:

Methods: microdialysis, blood sampling, bronchoalveolar lavage

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

intubated patients, intensive care

Criteria

Inclusion Criteria:

  • endotracheal intubation; pneumonia or complicated abdominal infection or complicated urinary tract infection

Exclusion Criteria:

  • allergy to doripenem, hemodialysis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01414959

Contacts
Contact: markus zeitlinger, md 0043140400 ext 2981 markus.zeitlinger@meduniwien.ac.at

Locations
Austria
Med. Univ. of Vienna Recruiting
Vienna, Austria, 1090
Contact: robert sauermann, md         
Contact: markus zeitligner, md         
Sponsors and Collaborators
Medical University of Vienna
Investigators
Principal Investigator: Markus Zeitlinger, MD Medical Universit of Vienna
  More Information

No publications provided

Responsible Party: Markus Zeitlinger, Professor Dr., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01414959     History of Changes
Other Study ID Numbers: Dori_MD_ICU
Study First Received: August 10, 2011
Last Updated: September 5, 2011
Health Authority: Austria: Ethikkommission

Keywords provided by Medical University of Vienna:
intensive care patient
intubation
(please change wording as you like!)

Additional relevant MeSH terms:
Communicable Diseases
Infection
Intraabdominal Infections
Urinary Tract Infections
Urologic Diseases

ClinicalTrials.gov processed this record on November 25, 2014